Benefits
Joint comfort
The only trial cited here tested 5-Loxin, an AKBA-standardized boswellia extract made by a different company, not AKBAMax. In that placebo-controlled study, adults already diagnosed with knee osteoarthritis reported less pain and better physical function than adults on placebo. The research group was linked to the maker of 5-Loxin. Nothing cited here shows what AKBAMax does for joint comfort in people who do not have osteoarthritis.
Anti-inflammatory support
AKBA blocks the 5-LOX enzyme in laboratory studies, which is the usual proposed explanation for how boswellia works. That is test tube work, not a measurement in people, and no study cited on this page measured inflammation markers in anyone taking AKBAMax.
Mobility and flexibility
No cited study measured range of motion or everyday movement for this extract. The single trial on this page, of a different company's extract, scored pain and physical function questionnaires in people with diagnosed knee osteoarthritis.
Mechanism of action
5-LOX inhibition
In laboratory studies AKBA inhibits an enzyme called 5-lipoxygenase, which lowers production of signaling molecules called leukotrienes. This is a proposed explanation, not something confirmed in people taking this extract; the one trial cited here measured symptom questionnaires, not leukotrienes.
Cartilage protection
Cartilage protection is a laboratory stage idea based on lower inflammatory enzyme activity. No study cited on this page looked at cartilage in people, so this should be treated as a theory rather than a proven effect.
Clinical trials
Double-blind, randomized, placebo-controlled study of 5-Loxin, an AKBA-enriched Boswellia serrata extract sold by a different company, in adults with diagnosed knee osteoarthritis. The authors were linked to the maker of 5-Loxin, and AKBAMax itself was not tested. (Sengupta et al. 2008, Arthritis Research and Therapy)
Adults already diagnosed with knee osteoarthritis, not healthy adults.
5-Loxin improved pain and physical function scores compared with placebo in these patients. That is evidence for 5-Loxin, from a research group linked to its manufacturer, and it is not evidence for AKBAMax. No trial of AKBAMax has been published.